Trial · NCT07889544
Prospective Comparison of Pro-Adrenomedullin, C-Reactive Protein, and Neutrophil-to-Lymphocyte Ratio for Diagnosing Acute Appendicitis
NCT07889544, Recruiting, Bursa Yuksek Ihtisas Training and Research Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prospective Comparison of Pro-Adrenomedullin, C-Reactive Protein, and Neutrophil-to-Lymphocyte Ratio for Diagnosing Acute Appendicitis. Trials, record NCT07889544. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889544
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prospective Comparison of Pro-Adrenomedullin, C-Reactive Protein, and Neutrophil-to-Lymphocyte Ratio for Diagnosing Acute Appendicitis
- NCT number
- NCT07889544
- Status
- Recruiting
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
- Conditions
- Acute Appendicitis
- Interventions
- Serum Pro-Adrenomedullin Measurement
- First posted
- 2026-10-22
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diagnostic Accuracy of Serum Pro-Adrenomedullin for Acute Appendicitis | At initial clinical assessment (baseline); diagnostic status confirmed during the index hospitalization. | The diagnostic accuracy of serum pro-adrenomedullin (Pro-ADM) for distinguishing patients with acute appendicitis from healthy controls will be assessed using the area under the receiver operating characteristic curve (AUC-ROC). Higher AUC values indicate better diagnostic discrimination. Sensitivity and specificity at the identified diagnostic cutoff will also be calculated. |
| Secondary | Comparison of the Diagnostic Accuracy of Pro-Adrenomedullin, C-Reactive Protein, and Neutrophil-to-Lymphocyte Ratio | At initial clinical assessment (baseline). | The diagnostic performance of Pro-Adrenomedullin (Pro-ADM), C-reactive protein (CRP), and neutrophil-to-lymphocyte ratio (NLR) will be evaluated using receiver operating characteristic (ROC) curve analysis. The area under the ROC curve (AUC) will be calculated for each biomarker, and their discriminatory performance for acute appendicitis will be compared. |
| Secondary | Optimal Diagnostic Cutoff Value of Serum Pro-Adrenomedullin | At initial clinical assessment (baseline). | A diagnostic cutoff value for serum Pro-Adrenomedullin (Pro-ADM) will be identified using receiver operating characteristic (ROC) curve analysis. Diagnostic sensitivity and specificity at the selected cutoff will be calculated to evaluate its ability to distinguish patients with acute appendicitis from healthy controls. |
| Secondary | Predictive Performance of Serum Pro-Adrenomedullin for Complicated Acute Appendicitis | From initial clinical assessment to completion of the index hospitalization. | The ability of serum Pro-Adrenomedullin (Pro-ADM) concentrations to discriminate complicated from uncomplicated acute appendicitis will be evaluated among patients with acute appendicitis. Receiver operating characteristic (ROC) curve analysis will be used to assess discriminatory performance, expressed as the area under the curve (AUC). |
| Secondary | Independent Diagnostic Contribution of Serum Pro-Adrenomedullin | At initial clinical assessment (baseline); diagnostic status confirmed during the index hospitalization. | The independent association between serum Pro-Adrenomedullin (Pro-ADM) concentration and acute appendicitis diagnosis will be evaluated using multivariable regression analysis, adjusting for available conventional inflammatory biomarkers and relevant clinical variables. The adjusted effect estimate and its 95% confidence interval will be reported. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889544
GET https://conductscience.org/api/trials/v1/NCT07889544/registered